Drug Trial Radar · NCT05355935
A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Mar 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Apr 27, 2022
Primary completion
Oct 7, 2022
Study completion Oct 7, 2022
Sponsor
- Lead sponsor
- Insmed IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- May 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study has 2 Parts: The primary purpose of Part 1 is to determine the supratherapeutic dose of brensocatib to be used in Part 2 of the study. The primary purpose of Part 2 is to assess brensocatib's potential for prolonging the QT interval.
Conditions
- Healthy Volunteer
Interventions
BrensocatibDrug
Oral tablet.
MoxifloxacinDrug
Oral tablet.
PlaceboDrug
Oral tablet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants who Experienced at least one Treatment-Emergent Adverse Event (TEAE) as Assessed by Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0)Time frame: Up to Day 7
- Part 2: Placebo- and Baseline-Corrected QTcF (ΔΔQTcF)Time frame: Pre-dose and at multiple timepoints post-dose on Days 1 to 4 in each period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
USA001
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.